Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Research & Development: 2017-2024

Historic Research & Development for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to $327.6 million.

  • Apellis Pharmaceuticals' Research & Development fell 23.01% to $68.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.0 million, marking a year-over-year decrease of 7.03%. This contributed to the annual value of $327.6 million for FY2024, which is 7.57% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Research & Development of $327.6 million as of FY2024, which was down 7.57% from $354.4 million recorded in FY2023.
  • Apellis Pharmaceuticals' Research & Development's 5-year high stood at $387.2 million during FY2022, with a 5-year trough of $299.9 million in FY2020.
  • In the last 3 years, Apellis Pharmaceuticals' Research & Development had a median value of $354.4 million in 2023 and averaged $356.4 million.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Research & Development skyrocketed by 35.73% in 2020, and later dropped by 8.48% in 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Research & Development (Yearly) stood at $299.9 million in 2020, then rose by 15.32% to $345.9 million in 2021, then rose by 11.96% to $387.2 million in 2022, then decreased by 8.48% to $354.4 million in 2023, then declined by 7.57% to $327.6 million in 2024.